Magazine Article | March 1, 2023

Making The Right Deal For Biohaven

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

"You aren’t in control of what the acquisition offers are, but you are in control of whether you take them or not. And if you don’t take them, you better be able to demonstrate value.”

Biohaven Chairman and CEO Vlad Coric’s singular focus on maximizing the value of the company he’s led since 2015 paid off last year, by way of a $11.6 billion Pfizer buyout, the second largest biopharma acquisition in 2022 (just behind Amgen’s $18 billion purchase of Horizon Therapeutics). Instead of resting on his laurels (or joining Pfizer), however, Coric negotiated a second life for Biohaven, focused on developing a new slate of product candidates for neurological and neuropsychiatric diseases.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader